Annovis Bio (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap. The company is advancing ongoing Phase 3 and extension studies in Alzheimer's disease and Parkinson's disease. The article provides historical and scientific context for buntanetap's progression, with current trials showing approximately 70% enrollment in early Alzheimer's and 20% enrollment in Parkinson's, underscoring its focus on advancing neurodegenerative therapies toward key clinical and regulatory milestones.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The publication in The Scientist highlights the scientific foundation and potential impact of buntanetap, which could represent a significant advancement in the treatment of Alzheimer's and Parkinson's diseases.
This announcement is important because it provides insight into the development of buntanetap and its potential to address critical unmet needs in neurodegenerative diseases. Alzheimer's and Parkinson's affect millions worldwide, and current treatments primarily manage symptoms rather than targeting underlying disease mechanisms. If successful, buntanetap could offer a disease-modifying therapy that alters the course of these conditions.
For more information, the full press release is available at https://ibn.fm/bqtAL. Annovis Bio is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company. More details about the company can be found at www.annovisbio.com.
